US 11091555
Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11091555 (Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy) held by Five Prime Therapeutics, Inc. expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2300/00